By Walkup, Melodia, Kelly & Schoenberger.
On the heels of a report from the General Accounting Office criticizing the way the Food and Drug Administration (FDA) handles approvals of medical devices (such as the DePuy artificial hip), the U.S. Institute of Medicine issued a report recommending an overhaul of the approval process.
The Flawed 510(k) Clearance Process
The report from the Institute of Medicine identified multiple aspects of the 510(k) process that are flawed. For example, the “previous device” to which the new device is styled as “similar” can itself have received FDA clearance as a 510(k) equivalent of yet another device and may not itself have been tested for safety and effectiveness. Furthermore, drug and device makers may incorporate new technologies or “upgrades” into a new generation equivalent without submitting a full review.According to a study published in the Archives of Internal Medicine, a disproportionate number of the medical devices that have caused health problems and patient deaths — like malfunctioning defibrillators and faulty insulin infusion pumps — were approved through the 510(k) process.The Institute of Medicine said in its letter to the FDA that “the 510(k) process generally is not intended to evaluate the safety and effectiveness of medical devices and, furthermore, cannot be transformed into a premarket evaluation of safety and effectiveness.” It advised that a new method be developed for testing medical devices before market.The Medical Device Manufacturers Association has criticized the IOM report, alleging that efforts to overhaul the regulatory process would slow patient access to medical therapies. Not surprisingly, manufacturers want regulations loosened even further. “‘Safe’ means that the benefits of a drug or medical device outweigh its risks, not that it’s risk-free,” said Jack Lasersohn, a partner in a venture capital firm that funds the development of medical devices, in a story in the Los Angeles Times.Industry spokespeople argue for fewer preventative measures and increased post-market surveillance, essentially making consumers guinea pigs. They are lobbying for rules that weaken premarket testing and approval steps, claiming that the FDA needs to develop a better way to track adverse reactions after a device is on the market.Consumer groups such as Public Citizen disagree. They have criticized the 510(k) process, saying it favors the medical industry and puts consumers at risk as well as pointing out that there is currently no way to quickly analyze data in the FDA’s adverse event reporting database.But even if after-market tracking was improved, it would not be enough. In written testimony to a Senate committee examining the FDA’s processes, the main author of the Archives of Internal Medicine article stated that there is a need for more stringent testing of medical devices, particularly if they are “potentially dangerous in predictable ways.”